Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19972227 | 0.88 | KMT2A (0.38) | ALDH1A1MAPTKMT2A | |
| SCHEMBL756201 | 0.86 | HTT (0.32) | ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL1096505 | 0.85 | KCNA5 (0.37) | ALDH1A1KMT2A | |
| SCHEMBL4428619 | 0.82 | ALDH1A1 (0.48) | ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL28296983 | 0.81 | ALDH1A1 (0.36) | ALDH1A1MAPTHTTCES2CES1 | |
| SCHEMBL1105718 | 0.81 | KCNA5 (0.40) | ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL19985861 | 0.79 | KMT2A (0.38) | ALDH1A1MAPTKMT2A | |
| SCHEMBL19988401 | 0.78 | KDM4E (0.37) | ALDH1A1MAPTKMT2A | |
| SCHEMBL9997229 | 0.76 | CES2 (0.42) | ALDH1A1MAPTNR3C1NR3C2CES2 | |
| SCHEMBL14920601 | 0.74 | HTT (0.34) | ALDH1A1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515902-A1 | 6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL | Grünenthal GmbH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-10265310-B2 | 6-membered cyclic amines or lactames substituted with urea and phenyl | Grünenthal GmbH (DE) | 2019-04-23 | — | — | US | disclosed |
| US-10265310-B2 | 6-membered cyclic amines or lactames substituted with urea and phenyl | Grünenthal GmbH (DE) | 2019-04-23 | — | — | US | disclosed |
| WO-2018054549-A1 | 6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL | Grünenthal GmbH (DE) | 2018-03-29 | — | — | WO | disclosed |
| US-20180078541-A1 | 6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL | Grünenthal GmbH (DE) | 2018-03-22 | — | — | US | disclosed |
| US-20180078541-A1 | 6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL | Grünenthal GmbH (DE) | 2018-03-22 | — | — | US | disclosed |
| US-20180078541-A1 | 6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL | Grünenthal GmbH (DE) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078541-A1 | 6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL | FPR2, FPR1, FPR3 | ALDH1A1 3156/4885MAPT 4276/4885HTT 3532/4885 |
| US-10265310-B2 | 6-membered cyclic amines or lactames substituted with urea and phenyl | FPR2, FPR1, FPR3 | ALDH1A1 3156/4885MAPT 4276/4885HTT 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.